|Potently neutralizing and protective human antibodies against SARS-CoV-2|
SJ Zost, P Gilchuk, JB Case, E Binshtein, RE Chen, JP Nkolola, A Schäfer, ...
Nature 584 (7821), 443-449, 2020
|Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains|
SJ Zost, K Parkhouse, ME Gumina, K Kim, SD Perez, PC Wilson, ...
Proceedings of the National Academy of Sciences 114 (47), 12578-12583, 2017
|Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition|
AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein, AN Loes, SK Hilton, ...
Cell host & microbe 29 (1), 44-57. e9, 2021
|Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season|
SL Linderman, BS Chambers, SJ Zost, K Parkhouse, Y Li, C Herrmann, ...
Proceedings of the National Academy of Sciences 111 (44), 15798-15803, 2014
|Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein|
SJ Zost, P Gilchuk, R Chen, JB Case, JX Reidy, A Trivette, RS Nargi, ...
Nature Medicine 26, 1422-1427, 2020
|A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine|
NC Wu, SJ Zost, AJ Thompson, D Oyen, CM Nycholat, R McBride, ...
PLoS pathogens 13 (10), e1006682, 2017
|Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies|
RE Chen, X Zhang, JB Case, ES Winkler, Y Liu, LA VanBlargan, J Liu, ...
Nature medicine 27 (4), 717-726, 2021
|Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies|
N Pardi, K Parkhouse, E Kirkpatrick, M McMahon, SJ Zost, BL Mui, ...
Nature communications 9 (1), 1-12, 2018
|Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin|
JM Lee, R Eguia, SJ Zost, S Choudhary, PC Wilson, T Bedford, ...
Elife 8, e49324, 2019
|Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein|
N Suryadevara, S Shrihari, P Gilchuk, LA VanBlargan, E Binshtein, ...
Cell 184 (9), 2316-2331. e15, 2021
|Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens|
SJ Zost, NC Wu, SE Hensley, IA Wilson
The Journal of infectious diseases 219 (Supplement_1), S38-S45, 2019
|Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection|
ES Winkler, P Gilchuk, J Yu, AL Bailey, RE Chen, Z Chong, SJ Zost, ...
Cell 184 (7), 1804-1820. e16, 2021
|Human influenza A virus hemagglutinin glycan evolution follows a temporal pattern to a glycan limit|
MO Altman, M Angel, I Košík, NS Trovão, SJ Zost, JS Gibbs, L Casalino, ...
MBio 10 (2), e00204-19, 2019
|Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail|
J Dong, S Zost, A Greaney, TN Starr, AS Dingens, EC Chen, R Chen, ...
|Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein–Based Influenza Vaccines During the 2017–2018 Season|
S Gouma, SJ Zost, K Parkhouse, A Branche, DJ Topham, S Cobey, ...
Clinical Infectious Diseases 71 (6), 1447-1453, 2020
|Identification of antibodies targeting the H3N2 hemagglutinin receptor binding site following vaccination of humans|
SJ Zost, J Lee, ME Gumina, K Parkhouse, C Henry, NC Wu, CCD Lee, ...
Cell reports 29 (13), 4460-4470. e8, 2019
|In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains|
M Diamond, R Chen, E Winkler, J Case, I Aziati, T Bricker, A Joshi, ...
|Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface|
SJ Zost, J Dong, I Gilchuk, P Gilchuk, NJ Thornburg, S Bangaru, N Kose, ...
bioRxiv, 2020.12. 31.424868, 2021
|Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition|
KJ Kramer, NV Johnson, AR Shiakolas, N Suryadevara, S Periasamy, ...
|Protective pan-ebolavirus combination therapy by two multifunctional human antibodies|
P Gilchuk, CD Murin, RW Cross, PA Ilinykh, K Huang, N Kuzmina, ...